GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haw Par Corp Ltd (OTCPK:HAWPF) » Definitions » Debt-to-EBITDA

Haw Par (Haw Par) Debt-to-EBITDA : 0.12 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Haw Par Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Haw Par's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.0 Mil. Haw Par's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $21.4 Mil. Haw Par's annualized EBITDA for the quarter that ended in Dec. 2023 was $183.5 Mil. Haw Par's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Haw Par's Debt-to-EBITDA or its related term are showing as below:

HAWPF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.15   Max: 0.42
Current: 0.12

During the past 13 years, the highest Debt-to-EBITDA Ratio of Haw Par was 0.42. The lowest was 0.01. And the median was 0.15.

HAWPF's Debt-to-EBITDA is ranked better than
85.74% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs HAWPF: 0.12

Haw Par Debt-to-EBITDA Historical Data

The historical data trend for Haw Par's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haw Par Debt-to-EBITDA Chart

Haw Par Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.01 0.01 0.18 0.12

Haw Par Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.08 0.18 0.12 0.12

Competitive Comparison of Haw Par's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Haw Par's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haw Par's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haw Par's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Haw Par's Debt-to-EBITDA falls into.



Haw Par Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Haw Par's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 21.383) / 177.912
=0.12

Haw Par's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 21.383) / 183.496
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Haw Par  (OTCPK:HAWPF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Haw Par Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Haw Par's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Haw Par (Haw Par) Business Description

Traded in Other Exchanges
Address
401 Commonwealth Drive, No. 03-03 Haw Par Technocentre, Singapore, SGP, 149598
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates a majority of its revenue from the ASEAN countries.

Haw Par (Haw Par) Headlines

From GuruFocus

First Eagle Comments on Haw Par

By Holly LaFon Holly LaFon 04-24-2018

Singapore Based Haw Par Selling at a Discount to NAV

By Holmes Osborne, CFA Holmes Osborne, CFA 07-26-2016

Haw Par Stock Is Believed To Be Significantly Overvalued

By GF Value GF Value 03-31-2021